Search results for "triglyceridemia"

showing 10 items of 85 documents

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

La teneur en lipides du régime affecte les capacitésd'absorption intestinale et la triglycéridémie postprandiale: contribution du récepteur nucléaire…

2007

The dietary long chain fatty acid have crucial functions into the organism such as energysource, eicosanoïdes synthesis, gene regulation). The fat disposal is essential and depend onintestinal barrier. It is well known that intestinal fat absorption is efficient. However, we don'tif the high triglycerides bioavailability of gut is attributable to inborn properties or to acquiredproperties. To answer this question, mice were subjected to a high-fat diet (40%, w/w) during21 days. We have shown that high-fat induces : 1) intestinal LCFA uptake, 2) intestinalmitotic index which leads to an increase of intestinal relative mass, 3) expression of genesinvolved in fatty uptake (Fatty Acid Transport…

PPARβtriglyceridemiaintestinlipid-binding proteintriglycéridémie[OTHER] domain_otherproliférationsmall intestineabsorption
researchProduct

Emerging approaches for the treatment of hypertriglyceridemia.

2013

Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjec…

PharmacologyHypertriglyceridemiamedicine.medical_specialtyAtherogenic dyslipidemiabusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseBioinformaticsFish consumptionClinical PracticeEndocrinologyIncreased riskPostprandialInternal medicinecardiovascular diseases triglycerides hypertriglyceridemia triglyceride-lowering agentsmedicineIncreased triglyceridesHumansPharmacology (medical)Obese subjectsbusinessLife StyleHypolipidemic AgentsExpert opinion on pharmacotherapy
researchProduct

Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia

1992

Abstract The effect of gemfibrozil on lipidic, coagulative, and fibrinolytic pattern was studied in 20 patients with primary type IV hyperlipoproteinemia. After a 4-week stabilization period during which administration of lipid-lowering drugs was stopped and an isocaloric diet (20% protein, 30% fat, and 50% carbohydrates) was prescribed, 20 patients (12 men and 8 women; mean age, 38 ± 4 years; body mass index, 23.4 ± 1.5) suffering from primary hypertriglyceridemia were included in this study and treated for a 12-week period with gemfibrozil (600 mg BID). Every 4 weeks the following parameters were checked: glycemia, triglycerides, total cholesterol, high density lipoprotein-cholesterol, to…

Pharmacologymedicine.medical_specialtyFactor VIIbusiness.industrymedicine.medical_treatmentHypertriglyceridemiaAntithrombinmedicine.diseaseFibrinogenchemistry.chemical_compoundEndocrinologychemistryHemostasisInternal medicineFibrinolysismedicineGemfibrozillipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatormedicine.drugCurrent Therapeutic Research
researchProduct

Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia.

2015

Objective— Cyclic AMP responsive element–binding protein 3–like 3 ( CREB3L3 ) is a novel candidate gene for dominant hypertriglyceridemia. To date, only 4 kindred with dominant hypertriglyceridemia have been found to be carriers of 2 nonsense mutations in CREB3L3 gene (245fs and W46X). We investigated a family in which hypertriglyceridemia displayed an autosomal dominant pattern of inheritance. Approach and Results— The proband was a 49-year-old woman with high plasma triglycerides (≤1300 mg/dL; 14.68 mmol/L). Her father had a history of moderate hypertriglyceridemia, and her 51-year-old brother had triglycerides levels as high as 1600 mg/dL (18.06 mmol/L). To identify the causal mutation …

ProbandAdultMaleCandidate geneHeterozygoteSettore MED/09 - Medicina InternaHeredityAdolescentNonsense mutationDNA Mutational AnalysisPenetranceBiologymedicine.disease_causeSeverity of Illness IndexFrameshift mutationExonYoung AdultmedicineHumansGenetic Predisposition to DiseasetriglycerideCyclic AMP Response Element-Binding ProteinTriglyceridesAgedGeneticsAged 80 and overHypertriglyceridemiaMutationHypertriglyceridemiaMiddle Agedmedicine.diseasePenetrancePedigreePhenotypeCodon NonsenseFemalemutationCardiology and Cardiovascular MedicineBiomarkersArteriosclerosis, thrombosis, and vascular biology
researchProduct

New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors

2011

Microsomal triglyceride transfer protein (MTP) is involved in the synthesis of very low density lipoprotein in the liver. Its deficiency results in abetalipoproteinemia. MTP inhibitors target the assembly and secretion of apolipoprotein B-containing lipoproteins. These agents may potentially play a role, alone or in combination, in the treatment of hypercholesterolemia or hypertriglyceridemia. Clinical applications of MTP inhibitors initially focused primarily on high-dose monotherapy in order to produce substantial reductions in LDL-cholesterol levels but these proved to induce significant hepatic steatosis and transaminase elevations. However, likely orphan indications for MTP inhibitors,…

Very low-density lipoproteinApolipoprotein BHypercholesterolemiaFamilial hypercholesterolemiaLipoproteins VLDLPharmacologyMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundMicrosomesDrug DiscoveryClinical endpointHumansMedicineApolipoproteins BHypertriglyceridemiaPharmacologybiologybusiness.industryCholesterolAbetalipoproteinemiamedicine.diseaseAbetalipoproteinemiaBiochemistrychemistryMTP-inhibitors lipids lipoproteins atherosclerosis cardiovascular prevention.biology.proteinlipids (amino acids peptides and proteins)SteatosisCarrier ProteinsbusinessCurrent Pharmaceutical Design
researchProduct

Postprandial adaptation of intestinal lipid metabolism : role of CD36 and PPAR beta

2011

Postprandial hypertriglyceridemia is an emerging risk factor for cardiovascular diseases and is associated with metabolic syndrome, obesity and insulin resistance. The small intestine participates in the postprandial triglyceridemia since both the size and number of secreted chylomicrons modulate lipoprotein lipase activity (LPL). Chylomicron synthesis is a complex mechanism in which the lipidation of Apolipoprotein B48 (ApoB48) by the Microsomal Triglyceride Transfer Protein (MTP) and the transfer between reticulum and Golgi in which the Liver Fatty Acid Binding Protein (L -FABP) is involved are limiting steps. An intestinal fat-mediated adaptation in postprandial period has been demonstra…

[SDV.SA]Life Sciences [q-bio]/Agricultural sciences[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTriglycéridémie postprandialedigestive oral and skin physiologyPostprandial triglyceridemiaRécepteurPPAR betaPPAR béta[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyChylomicronslipids (amino acids peptides and proteins)CD36[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyReceptor
researchProduct

Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".

2018

Familial chylomicronaemia syndrome (FCS) is a rare, inherited disorder characterised by impaired clearance of triglyceride (TG)-rich lipoproteins from plasma, leading to severe hypertriglyceridaemia (HTG) and a markedly increased risk of acute pancreatitis. It is due to the lack of lipoprotein lipase (LPL) function, resulting from recessive loss of function mutations in the genes coding LPL or its modulators. A large overlap in the phenotype between FCS and multifactorial chylomicronaemia syndrome (MCS) contributes to the inconsistency in how patients are diagnosed and managed worldwide, whereas the incidence of acute hypertriglyceridaemic pancreatitis is more frequent in FCS. A panel of Eu…

[SDV]Life Sciences [q-bio]Diagnosis toolpopulation030204 cardiovascular system & hematologyburdenapoa50302 clinical medicineLoss of Function MutationRisk FactorsChylomicrons030212 general & internal medicineAge of OnsetHypolipidemic AgentsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Lipoprotein lipaseplasma triglycerideshyperlipoproteinemiaPrognosis3. Good healthUp-RegulationPhenotypeAcute pancreatitislipids (amino acids peptides and proteins)Hyperlipoproteinemia Type IAcute pancreatitis ; Familial chylomicronaemia syndrome ; Major hypertriglyceridaemia ; Multifactorial chylomicronaemiaCardiology and Cardiovascular MedicineFamilial chylomicronaemia syndromeAlgorithmsacute-pancreatitismedicine.medical_specialtyConsensushypertriglyceridemiaetiologyAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia/Decision Support TechniquesDiagnosis Differential03 medical and health sciencesAcute pancreatitis; Familial chylomicronaemia syndrome; Major hypertriglyceridaemia; Multifactorial chylomicronaemia; Cardiology and Cardiovascular MedicinePredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseAcute pancreatitiBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.GenotypingTriglyceridesPregnancyReceiver operating characteristicbusiness.industrysevereMultifactorial chylomicronaemiaReproducibility of Resultsmutationslipoprotein-lipase genemedicine.diseaseConfidence intervalAcute pancreatitisLipoprotein LipasePancreatitisCardiovascular System & CardiologyPancreatitisMajor hypertriglyceridaemiabusinessBiomarkersAtherosclerosis
researchProduct

Hypertriglyceridemia and Omega-3 Fatty Acids

1988

Recent studies by Bang and Dyerberg (1) have stimulated interest in the metabolism of omega-3 fatty acids and have suggested a link between the ingestion of these fatty acids in a diet and the low death rate from athersclerotic disease in Eskimos. In Japan, where fish consumption has traditionally been high, a concommitant shift in tissue lipid consumption favouring omega-3 polyunsaturated fatty acids has been interpreted as causative of a relatively low incidence of cardiovascular disease (1). When analyzing Eskimo food consumption, it became clear that the consumption of omega-3 PUFA is much higher besides a 50% reduction of saturated fat and a relatively high content of monounsaturated f…

chemistry.chemical_classificationCalorieChemistrySaturated fatHypertriglyceridemiamedicineIngestionCholesterol intakeMetabolismFood sciencemedicine.diseaseOmegaPolyunsaturated fatty acid
researchProduct

Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia …

2020

The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles' heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Societa Italiana Farmacologia (SIF)…

diabetes; dyslipidemia; hypercholesterolemia; hyperglycemia; hypertriglyceridemia; immunotherapy; metabolic effect; targeted therapy; Consensus; Humans; Immunologic Factors; Italy; Medical Oncology; Neoplasms; Physicians0301 basic medicinemedicine.medical_specialtyConsensusSettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentPatient riskhypertriglyceridemiaMedical OncologyTargeted therapy03 medical and health sciences0302 clinical medicineMultidisciplinary approachNeoplasmsPhysiciansmedicineHumansImmunologic FactorsIntensive care medicineAdverse effectdiabeteshypercholesterolemiabusiness.industrydyslipidemiametabolic effectHematologytargeted therapy030104 developmental biologyOncologyItalyClinical evidence030220 oncology & carcinogenesisMetabolic effectsPosition paperhyperglycemiaimmunotherapybusiness
researchProduct